A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

Stopped Meeting enrolment target (81 pat) will not be feasible within reasonable time.

Conditions

• Still's Disease, Adult-Onset
• Still's Disease, Juvenile-Onset

Interventions

• BIOLOGICAL: anakinra
• DRUG: Placebo

Sponsor

Swedish Orphan Biovitrum